1. Home
  2. SGA vs ELOX Comparison

SGA vs ELOX Comparison

Compare SGA & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$5.92

Market Cap

56.6M

ML Signal

HOLD

Logo Eloxx Pharmaceuticals Inc. Common Stock

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

HOLD

Current Price

$10.40

Market Cap

52.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGA
ELOX
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
56.6M
52.5M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
SGA
ELOX
Price
$5.92
$10.40
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $37.50
AVG Volume (30 Days)
16.1K
★ 19.4K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
★ 15.15%
N/A
EPS Growth
N/A
★ 41.67
EPS
★ N/A
N/A
Revenue
★ $124,829,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 5.65
N/A
52 Week Low
$6.55
$10.00
52 Week High
$12.76
$23.40

Technical Indicators

Market Signals
Indicator
SGA
ELOX
Relative Strength Index (RSI) 19.91 35.60
Support Level N/A N/A
Resistance Level $9.41 $14.65
Average True Range (ATR) 0.44 1.08
MACD -0.11 -0.18
Stochastic Oscillator 25.87 25.38

Price Performance

Historical Comparison
SGA
ELOX

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Share on Social Networks: